300 NORTH CAPITAL, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 174 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.

Quarter-by-quarter ownership
300 NORTH CAPITAL, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2015$736,000
+81.7%
2,609
+0.5%
0.16%
+74.2%
Q4 2014$405,000
-33.8%
2,595
+0.3%
0.09%
-42.6%
Q3 2014$612,0000.0%2,5880.0%0.16%
+7.3%
Q2 2014$612,000
-28.3%
2,5880.0%0.15%
-31.7%
Q1 2014$854,0002,5880.22%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2014
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders